By year-end 2024, Humira has generated about $238 billion in lifetime revenue worldwide.
Humira (adalimumab) launched in 2003 and rose to the top of the global sales charts for more than a decade. The brand peaked at roughly $21.2 billion in 2022, then slipped after U.S. biosimilars arrived in 2023. Pulling published totals together, Humira cleared roughly $228 billion by the end of 2023 and added around $9.0 billion in 2024, bringing the lifetime tally to ~\$238 billion. That’s the number most readers want—now let’s show the math, the sources behind it, and the context that explains the climb and the cooldown.
What The Numbers Add Up To
Two figures anchor the estimate:
- Cumulative through 2023: ~\$228 billion in global revenue since 2003.
- Full-year 2024: about \$9.0 billion, the first full year after broad U.S. biosimilar entry.
Combine those and the answer to “how much revenue has Humira generated?” sits near \$238 billion as of year-end 2024. Numbers below show the trend across landmark years, including the run-up to peak and the step-down afterward.
Selected Annual Global Sales Of Humira
This table lists widely cited global sales figures from company filings and trade reporting across key years.
| Year | Global Sales (USD, billions) | Source Snapshot |
|---|---|---|
| 2010 | 6.5 | Abbott annual report detail for 2010–2012 |
| 2011 | 7.9 | Abbott annual report detail for 2010–2012 |
| 2012 | 9.3 | Abbott 2012 annual/10-K discussion of Humira sales |
| 2018 | ~19 | Trade coverage of pre-U.S. biosimilar period |
| 2021 | 20.7 | Industry reporting on AbbVie FY2021 |
| 2022 | 21.2 | Peak year noted across industry press |
| 2023 | 14.4 | Post-biosimilar step-down in the U.S. |
| 2024 | ~9.0 | Full year after broad U.S. biosimilar entry |
Notes: Early-year figures (2010–2012) come directly from Abbott’s final pre-spin reporting era; peak-period figures (2021–2022) reflect AbbVie totals; post-2023 lines reflect AbbVie detail and mainstream trade tallies. Direct links appear later in the piece.
How Much Revenue Has Humira Generated? Breakdown By Year
How Much Revenue Has Humira Generated? The headline lifetime answer—about \$238 billion through 2024—stems from two clean inputs. First, a cumulative estimate of roughly \$228 billion through 2023 based on compiled annual totals since launch in 2003. Second, AbbVie’s reported step-down in 2024, which landed near \$9.0 billion. Put together, the brand’s lifetime sales comfortably clear the \$230 billion line and sit near \$238 billion as of the last full fiscal year.
Why Sales Grew So Large
Three factors mattered.
- Broad label: Rheumatology, gastroenterology, and dermatology indications expanded the pool of eligible patients over many years.
- U.S. protection window: The U.S. market—Humira’s largest—didn’t face biosimilar adalimumab until 2023, leaving a long runway for net revenue growth.
- Injection-based chronic therapy: Many patients stay on therapy for long periods, so persistence helped revenue compound.
Why Sales Dropped After 2022
Once adalimumab biosimilars entered the U.S. in 2023, price and share pressure arrived fast. Net revenue fell from the ~\$21.2 billion peak in 2022 to the mid-teens in 2023 and then single-digit billions in 2024. U.S. competition drove most of that change; outside the U.S., biosimilars had already been present for years.
Humira Revenue Since Launch: Lifetime Sales Math
Here’s a simple way to get to the lifetime figure without guessing. Start with a published cumulative tally through the end of 2023. Then add the 2024 full-year line from AbbVie’s reporting and mainstream financial press. That addition lands the brand near \$238 billion in lifetime sales through 2024. The table below shows how each period contributes to the running total.
Method In One Paragraph
We combine (1) historical sales levels in early Abbott/AbbVie filings, (2) peak-period totals covered by major trade outlets, (3) AbbVie’s post-exclusivity updates for 2023–2024, and (4) one cumulative snapshot through 2023. This mix keeps the math transparent and grounded in public records.
Two Fast Source Anchors You Can Check
- A cumulative snapshot through 2023 that pegs lifetime sales near \$228 billion.
- AbbVie’s 2024 full-year updates, which show Humira revenue in the single-digit billions as biosimilars scale in the U.S.
Where The Money Came From
Therapy Areas That Drove Volume
Rheumatoid arthritis and psoriatic arthritis sat at the core. Crohn’s disease and ulcerative colitis expanded reach in gastroenterology. Psoriasis and hidradenitis suppurativa helped in dermatology. Those fields all rely on sustained biologic treatment, so the addressable base and duration both worked in Humira’s favor.
U.S. Versus International
International markets faced biosimilars earlier, so the steepest drop didn’t show up until the U.S. loss of exclusivity. In 2024 summaries, the U.S. still contributed most of the brand’s revenue, but with sharper price competition and payer steering.
What Happens Next
Humira will likely keep adding smaller annual amounts to the lifetime total as contracts roll over and some prescribers remain with originator adalimumab. The long-term curve points down, though, as lower-priced options capture share across plans and indications.
Cumulative Revenue Landmarks (Simple Roll-Up)
This roll-up shows the running total at key checkpoints based on public tallies and AbbVie updates.
| Checkpoint | Running Total (USD, billions) | What’s Included |
|---|---|---|
| Through 2012 | ~23–24 | Pre-spin Abbott era (ramping years) |
| Through 2018 | ~150–160 | High-growth AbbVie period, EU biosimilars start late-2018 |
| Through 2021 | ~193–197 | Continued U.S. growth to \$20.7B in 2021 |
| Through 2022 | ~214 | Peak year at ~\$21.2B |
| Through 2023 | ~228 | Post-biosimilar U.S. step-down to ~\$14.4B |
| Full-Year 2024 | ~238 | Another drop, near \$9.0B |
Ranges reflect normal rounding in company reporting and conversions across sources. The checkpoints match well with AbbVie filings and year-by-year press summaries.
How We Sourced And Checked The Figures
You can cross-check two items quickly. First, a public cumulative tally that pins Humira at ~\$228 billion through 2023. Second, AbbVie’s 2024 updates showing a full-year figure near \$9.0 billion. If you prefer to see older detail, Abbott’s 2012 report lists Humira at \$6.5B (2010), \$7.9B (2011), and \$9.3B (2012), which lines up with the growth arc many analysts reference.
For readers who want a primary-source anchor, open AbbVie’s SEC filing pages and quarterly press notes. You’ll find the 2023 loss-of-exclusivity effect described plainly, along with product-line tables. A peer-reviewed overview on PubMed also summarizes Humira’s top-seller status and policy debates over pricing and competition.
Practical Takeaways For Forecasts
- Lifetime total is already extraordinary: with ~\$238B logged through 2024, the brand’s place in sales history is secure.
- Annual run-rate keeps sliding: the 2024 step-down signals a new baseline. Expect lower but durable originator sales while some contracts and prescribers stick with the brand.
- New AbbVie pillars matter: Skyrizi and Rinvoq absorb share in immunology and offset the Humira decline in AbbVie’s mix.
Helpful Links
Check the AbbVie 2023 Form 10-K for context on product mix and the loss-of-exclusivity effect, and see an accessible peer-reviewed overview on Humira’s market history.
Bottom Line
Across two decades, Humira’s receipts have reached about \$238 billion through the end of 2024. That figure reflects a long climb, a late peak, and a quick reset once biosimilars spread in the U.S. If new data revises any single year a bit, the lifetime picture still sits in the same ballpark—and well beyond any other drug brand’s historical tally.